Therapeutic and diagnostic anti-loxl4 antibodies
AssigneeChristian-Albrechts-Universität zu Kiel
InventorTibor Görögh
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for the detection, prevention and treatment of primary and metastatic neoplastic diseases, including, but not limited to, human carcinomas, in particular head and neck squamous cell carcinoma. In particular, an antibody and antigen-binding fragment as well as variants thereof are provided that bind to an epitope of LOXL4 in the cytoplasm and/or on the cell surface of tumor cells, which are useful in the diagnosis and especially the treatment of a tumor which expresses LOXL4.
Claims17
1-15. (canceled)
A method of treating tumor cells which express lysyl oxidase-like 4 (LOXL4) which comprises contacting the cells with an antibody that binds to an epitope of LOXL4 in the cytoplasm or on the cell surface, or both, of such tumor cells, or an antigen-binding fragment of such an antibody, so as to treat the tumor cells.
An anti-LOXL4 antibody produced by hybridoma LOXL4-P (DSM ACC3233) or an antibody or antibody fragment comprising at least one complementarity determining region (CDR) of the anti-LOXL4-P antibody produced by hybridoma LOXL4-P (DSM ACC3233) and capable of binding to an epitope of LOXL4 in the cytoplasm, and/or on the cell surface, of tumor cells, wherein the epitope comprises or consists of the amino acid sequence KVWDLKMR (SEQ ID NO:
- 1).
A polynucleotide encoding at least the variable region of one immunoglobulin chain of an antibody or antigen-binding fragment of such an antibody, wherein the antibody is capable of binding to an epitope of LOXL4 in the cytoplasm, and/or on the cell surface, of tumor cells, wherein the epitope comprises or consists of the amino acid sequence KVWDLKMR (SEQ ID NO:
- 1).
Dependencies are inferred from the claim text.